Ascendis Pharma A/S Stock

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:26:50 2024-05-28 pm EDT 5-day change 1st Jan Change
126.6 USD -2.93% Intraday chart for Ascendis Pharma A/S +2.99% +0.45%
Sales 2024 * 444M 483M Sales 2025 * 727M 791M Capitalization 6.89B 7.5B
Net income 2024 * -281M -306M Net income 2025 * 8M 8.7M EV / Sales 2024 * 16.8 x
Net Debt 2024 * 570M 620M Net Debt 2025 * 277M 301M EV / Sales 2025 * 9.85 x
P/E ratio 2024 *
-24.8 x
P/E ratio 2025 *
2,483 x
Employees 879
Yield 2024 *
-
Yield 2025 *
-
Free-Float 10.3%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.75%
1 week+7.71%
Current month-5.80%
1 month-4.04%
3 months-16.05%
6 months+42.66%
Current year+3.54%
More quotes
1 week
122.73
Extreme 122.7266
133.09
1 month
116.63
Extreme 116.625
143.99
Current year
116.63
Extreme 116.625
161.00
1 year
83.75
Extreme 83.75
161.00
3 years
61.58
Extreme 61.5791
178.71
5 years
61.58
Extreme 61.5791
183.98
10 years
11.92
Extreme 11.92
183.98
More quotes
Managers TitleAgeSince
Founder 65 06-08-31
Director of Finance/CFO 50 16-08-07
Chief Tech/Sci/R&D Officer 50 20-04-30
Members of the board TitleAgeSince
Founder 65 06-08-31
Chairman 51 14-10-31
General Counsel 53 07-12-31
More insiders
Date Price Change Volume
24-05-28 126.5 -2.98% 62 920
24-05-24 130.4 +0.75% 250,225
24-05-23 129.4 -1.30% 405,348
24-05-22 131.1 +6.75% 1,393,999
24-05-21 122.8 +1.47% 682,413

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
120.1 EUR
Average target price
168.3 EUR
Spread / Average Target
+40.06%
Consensus